VIOLIN Logo
VO Banner
Search: for Help
Vaxvec Home
Introduction
Statistics
News and Updates
Vaxvec Vectors
Vaxvec Vaccines
Vaxvec Antigens
VaxvecAg BLAST
Selected Vectors
B. abortus RB51 vector
RSV vaccine vector
SL3261 vaccine vector
VSV vaccine vector
Data Submission
Data Exchange
Data Download
Documentation
FAQs
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

CAdVa-Filoviruses (EbMarburg viruses) cAdVaxM(fus)
Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004645
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • GP from Musoke Marburgvirus gene engineering:
    • Type: Recombinant vector construction
    • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • GP from Marburg virus Ravn gene engineering:
    • Type: Recombinant vector construction
    • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • GP from Marburg virus Ci67 gene engineering:
    • Type: Recombinant vector construction
    • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Three novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004646
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • GP from Musoke Marburgvirus gene engineering:
    • Type: Recombinant vector construction
    • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • GP from Marburg virus Ravn gene engineering:
    • Type: Recombinant vector construction
    • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • GP from Marburg virus Ci67 gene engineering:
    • Type: Recombinant vector construction
    • Description: Novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: Three novel gene-based vaccine candidates which express the viral glycoprotein (GP) from either the Ci67, Ravn or Musoke strain of MARV (Wang et al., 2006).
  • Immunization Route: Intramuscular injection (i.m.)
References References
Wang et al., 2006: Wang D, Schmaljohn AL, Raja NU, Trubey CM, Juompan LY, Luo M, Deitz SB, Yu H, Woraratanadharm J, Holman DH, Moore KM, Swain BM, Pratt WD, Dong JY. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses. Vaccine. 2006 Apr 5; 24(15); 2975-86. [PubMed: 16530297 ].
Wang et al., 2006: Wang D, Schmaljohn AL, Raja NU, Trubey CM, Juompan LY, Luo M, Deitz SB, Yu H, Woraratanadharm J, Holman DH, Moore KM, Swain BM, Pratt WD, Dong JY. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses. Vaccine. 2006 Apr 5; 24(15); 2975-86. [PubMed: 16530297 ].